Actinogen Medical — XanaMIA Phase IIb/III study marches on
Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive...
213 Views
Actinogen Medical - A$11.1m capital raise completed
Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its...
256 Views
Actinogen Medical - Funding in place to complete XanaMIA Phase IIb
Actinogen Medical announced a capital increase of up to A$11.1m on 18 September, consisting of the successful completion of an A$8.1m (gross) share...
334 Views
Actinogen Medical - Further positive XanaCIDD results on depression
New data were revealed from Actinogen Medical’s ongoing analysis of the now-completed XanaCIDD study that support the view that the company’s lead...
274 Views
Actinogen Medical - XanaCIDD data narrow the focus in depression
While the results from Actinogen’s XanaCIDD exploratory Phase IIa study in patients with major depressive disorder (MDD) did not meet the primary...
375 Views